Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
It seems few can resist the revenue that can await a cancer treatment.
After over a decade extending the half-life of medicines for J&J, Genentech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
